Phase III MISSION trial of sorafenib monotherapy in heavily pretreated patients with non-small cell lung cancer
EGFR status may help select patients who will benefit most
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
EGFR status may help select patients who will benefit most
Pancreatic cancer is notoriously difficult to treat and is still associated with a dismal prognosis, despite decades of research.
Phase III, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in oesophageal cancer progressing after chemotherapy
Four new pharmacological interventions show promise in crizotinib naive patients or in overcoming resistance to ALK and tyrosine kinase inhibitors
Updated results of phase III START trial presented at ESMO 2012
This year’s ESMO Congress will provide us with a first glimpse at some new drugs that may eventually become cancer treatments in the future.
ESMO’s Young Oncologist Programme began on Friday afternoon with a master class exploring the development of clinical trial protocols.The presenters reviewed issues around trial design in the era of targeted agents and biomarkers.
BRAF and MEK drug combinations reveal more understanding in acquired resistance to melanoma treatment
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.